There is only one way to be on the radar of institutional investors . . . the company MUST BE VETTED by a well known banker. A positive announcement of major proportions like a licensing deal will get some increase in valuations but not near as much if the company had a big name behind it.
I believe Ampio's management is great at running their business and developing their pipeline in record time and at record low cost, BUT . . . they tried to save money and dilution staying with small unknown bankers . . . AND THAT HAS COST SHAREHOLDERS HUNDREDS AND HUNDREDS OF MILLIONS OF DOLLARS IN LOW VALUATIONS BECAUSE FEW INVESTORS WILL TAKE A RISK ON A COMPANY ENDORSED ONLY BY FORDHAM OR AEGIS. I have done several comps of lesser pipelines and based on those comps, Ampio would be selling at least $1 billion in market cap or $20 . . . before any big news hits!
The day the company brings a major banker on board is the day the stock will finnaly trade at the valuations it deserves. It is well worth any dilution to have access to all of Wall Street instead of only Fordham and Aegis customers.
In the meanwhile, shares should perform only okay but not near up to their true potential. All the good news in the world cannot buy the value of an endorsement from a big banker that opens the floodgates to the massive amount of investors looking for a company like Ampio.
Racavalli - How do you suggest AMPE accomplish this? No analyst from a major bank is going to endorse AMPE until they have a product approved by the FDA. Your suggestion that AMPE has created the valuation issue by using small (obscure - my words) investment bankers is nonsense. AMPE is using the available resources. Once they get approval of anything we get not one but probably several endorsements. Today there are institutional investors that want a part of AMPE but at a high cost. AMPE is trying to juggle all the drugs to keep all if possible for the shareholders as long as possible to maximize shareholder value.
Absolutely incorrect. Ampio;s story is enough to attract the top bankers in the industry who would all love to be their banker. Ampio is the problem because management feels they would be diluting their shareholders which is penny wise and pound foolish when you consider the extreme valuations that would be gained by such a move.
This problem will plague ampio for a long long time and it will result in lesser volumes and lesser valuations. Even if shares rise, they won't rise near as much .. . . and they are likely to fall back down once the shorts come back in to manipulate because it is easy to control a low volume stock.
It's absolutely amazing that only the shorts have figured this out and that management doesn't even care.
They just passively sit back and do nothing and let Fordham and Aegis run them into the ground.
you are living in a dream world if you think that ampio can ever achieve maximum valuations without having a big name banker on board. We live in highly risk averse times and most investors are not going to take a position in ANY company without the comfort of having a big and well known bankers name behind it.
i've been in this business since 1967 and that has always been true and it is even more so today.
yes ampio may go up on good news but the not nearly as much as it would have risen if investors saw that it was endorsed by a big name they trust.
ampio is highly undervalued today and will remain highly undervalued no matter how much news they release.
it would be far better for shareholders if the company changed its thinking that is penny wise and pound foolish . . . and paid the big dilution to a big banker so their shares could finally trade with big volumes and at much much much higher prices.
fordham and aegis are killing ampios shareholders and macaluso is not helping by passively sitting back and doing nothing
run some comps for yourself and you will see very clearly that ampio Would be selling well above $20 today if it had big bankers around them.